DOSAGE INDEX / SINGLE
Semax
Research, reported schedules and supply planning.
Review Semax rehabilitation research, acute imaging and negative animal findings without confusing biomarkers with lasting cognitive or clinical benefit.
Source: PeptideDosages.com. Independently written summaries of reported protocols, not validated treatment recommendations. Reviewed for transcription on September 21, 2026.
Research Protocol & Dosage
Source-reported examples · not treatment recommendations
- Amount
- 200–300 micrograms per administration, totaling 400–900 micrograms daily in its example
- Frequency
- Two or three times daily
- Cycle / observation period
- 5 days in its product-reference example
- Route / research model
- Intranasal
The source also discusses different study exposures. These cannot be combined into a single generic nasal-pump regimen.
Titration & progression
A dose range is not a titration schedule. No independently verified stepwise escalation has been established for this source-reported regimen.
Supply & Planning
Compare vial strengths here. A different vial size changes the available material, not the biological dose.
Diluent & formulation
Intranasal formulation: preservative, tonicity and delivery-device compatibility must be verified. Injectable bacteriostatic water is not assigned as the default nasal vehicle.
Vial comparison
No single complete schedule is resolved for this entry. Enter a documented total to compare strengths; the calculator does not select a regimen.
| Vial strength | Vials needed |
|---|---|
| 5 mg | Enter a total |
| 10 mg | Enter a total |
Enter a positive material total.
Material minimum only: round total material ÷ vial content up to a whole vial. Actual supply may be higher because of single-use packaging, discard dates, dead space or losses. No validated multi-use storage period is assumed.
Reported Research Results
Selected observations from the cited research. Each finding retains its study population, formulation and limitations.
- A 2017 experiment studied Semax and Selank in rats with 6-OHDA-induced Parkinson-like injury. Neither peptide improved the reported motor-activity measure or passive defensive behavior. The anxiety-related improvement was attributed to Selank, not Semax. [3]
- A 2018 report examined 110 patients after ischemic stroke, divided into earlier and later rehabilitation groups and into subgroups with or without Semax. Investigators assessed plasma BDNF, motor performance and Barthel Index scores. They reported increased BDNF and more favorable Barthel-score changes with Semax. The accessible abstract does not provide enough detail to establish a fully appraised blinded, randomized effect estimate. [1]
- In a 2020 experiment involving 52 healthy participants, researchers compared resting-state fMRI measurements around administration of Semax, Selank or placebo. They reported group and time differences in connectivity between the right amygdala and temporal cortical regions. The abstract describes network measurements, not a demonstrated long-term improvement in memory or daily performance. [2]
Sourcing & Vendor Information
No compound-specific affiliate destination is listed here yet. Browse the Vendors Index for the available supplier records and disclosed relationships.
Sources & Further Reading
Medical publications and supporting literature from the corresponding protocol bibliographies, combined across vial strengths. Supplier and commercial catalog references are excluded. Duplicate destinations appear once. Inclusion does not mean that a paper validates the reported dose, or that an ingredient study tests the finished blend.
Bibliography checked September 22, 2026: 14 entries mapped from 2 source pages. Medical and supporting references are retained below; supplier entries are excluded.
- Original rehabilitation study
- original imaging study
- Slominsky and colleagues, original abstract
- FDA risk resource
- Kaplan et al. (1996)Further reading · Listed in reference bibliography.
- Lebedeva et al. (2018)Further reading · Listed in reference bibliography.
- Trows et al. (2014)Further reading · Listed in reference bibliography.
- U.S. Food and Drug AdministrationRegulatory / product information · Listed in reference bibliography.
- Deigin et al. (2022)Further reading · Listed in reference bibliography.
Reported schedule reference: PeptideDosages.com. Research findings are summarized independently from the listed sources.